Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …

Abstract The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker
Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on …

Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has
been recommended in clinical practice guidelines to reduce morbidity and mortality in …

The clinical syndrome of heart failure (HF) can be described as the reduced capacity of the
heart to deliver blood throughout the body. To compensate for inadequate tissue perfusion …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

Despite significant advances in the last 30 years in reducing morbidity and mortality from
heart failure with reduced ejection fraction (HFrEF) with pharmacological and device-based …

With an estimated prevalence of 5.8 million in the USA and over 23 million people
worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of …

This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …

Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …